Michael Spellacy, Board Chair and Director Non-Executive at Enfusion, is appointed by the company

NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of cloud-native software-as-a-service (SaaS) solutions for investment managers, today announced that on January 9, 2023, its Board of Directors (the “Board”) had appointed Michael Spellacy, as Board Chair, effective immediately.

“We are delighted with the addition of Michael Spellacy and are fortunate to have a leader with Mr. Spellacy’s strategic experience as our next Board chair. We look forward to benefiting from Michael’s deep understanding of our clients’ business requirements, and his familiarity with investment management technology. I can’t think of a more suitable candidate to lead the Board going forward,” said Kathleen DeRose, Interim Chair of the Board, on behalf of the Board of Directors. “With our recent executive leadership transitions in place, the company is well-positioned to advance our strategy, execute on our plans, and focus on delivering even greater value for our stakeholders.”

He joins Brad Bernstein and Roy Luo as board directors. Jan Hauser, Jan Hauser. Kathleen DeRose. Deirdre SOMERS is the Enfusion Chief Executive Officer.

“It is my pleasure to welcome Michael to Enfusion’s Board. His combination of technology experience and a broad strategic view of capital markets infrastructure and investment management is a unique blend. We look forward to leveraging Michael’s operating track record and strategic insight to drive Enfusion’s culture of execution, technology innovation and focus on client success,” said Oleg Movchan. “This appointment could not come at a better time as Enfusion continues to build out its rapidly growing, durable and resilient software and services platform in the context of a highly uncertain macroeconomic environment and transformational technology shifts. I would also like to take this opportunity, on behalf of Enfusion and the Board, to thank Kathleen DeRose for her leadership as Interim Chair during this transition period for the company.”

Michael Spellacy currently serves as the Chief Executive Officer for Atlas Crest Investment Corporation. He is widely recognized worldwide as a technology and asset manager. He was most recently a Senior Managing Director and the leader of Accenture’s global Capital Markets practice, where he was responsible for the industry group’s overall vision and strategy, investment priorities, and supporting an ecosystem of alliance partners. Before joining Accenture, Mr. Spellacy worked as a Senior Partner at PwC’s wealth management practice and as a partner with Broadhaven Capital Partners. This independent bank and private equity investor serves the technology and financial sectors. He holds a bachelor of science degree in Economics from London School of Economics, and he also has an MBA from University of Hartford.

“I am excited to join this experienced, capable Board of Directors, and such a dynamic business, and to lead the Board as its new Chair at an important inflection point for the company”, said Mr. Spellacy. “I look forward to working with the executive leadership to realize Enfusion’s ambitious growth plans.”

Information about Enfusion

Enfusion’s investment management software-as-a-service (SaaS) platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one cloud-native system. Enfusion’s software, analytics and managed services for the middle and back-office creates an enterprise culture of data-driven, real-time intelligence that boosts agility and drives growth. Enfusion has over 800 partners from 10 international offices that span four continents.

Forward-looking statements

Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (“Exchange Act”), including expectations regarding future financial performance. These forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “could,” “will,” and variations of such words or similar expressions. These forward-looking statements are intended to be protected by Section 27A and Section 21E, respectively. We make this statement in order to comply with these safe harbor provisions. These forward-looking statement reflect our current view about our plans, intentions and expectations regarding our prospects. This information is based on our knowledge and our assumptions. We believe our intentions, plans, expectations, strategies, and prospects, as expressed in these forward-looking statements, are realistic. However, it is impossible to predict whether the plans, plans, or expectations will actually be realized or accomplished. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control, such as those set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 that was filed with the Securities and Exchange Commission (“SEC”) on March 30, 2022, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022 that was filed with the SEC on August 10, 2022, and our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022 that was filed with the SEC on November 10, 2022. Forward-looking statements are not subject to revision, regardless of whether they have been made in response to new information or future events.

Source Code: ENFN IR

Contacts

Media
Prosek Partners

pro-enfusion@prosek.com

Investors
Ignatius Njoku

investors@enfusion.com